Recent Quotes
My Watchlist
Indicators
Central Oregon Stock Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Myriad Genetics, Inc. - Common Stock (NQ:MYGN)

2.860 -2.510 (-46.74%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 31, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Headline News about Myriad Genetics, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 Next >
News headline image
Myriad Genetics Q2 Earnings Call Highlights ↗
Myriad Genetics (NASDAQ:MYGN) reported second-quarter 2026 revenue of $190.7 million, down 11% from a year earlier, as a 1% decline in total test volume and a 9% decrease in revenue per test weighed on... 
Via MarketBeat
Topics Artificial Intelligence Earnings
Top movers in Friday's session ↗
Via Chartmill
News headline image
Why Myriad Genetics (MYGN) Shares Are Falling Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) fell 46.1% in the afternoon session after the company reported disappointing s... 
Via StockStory
Topics Artificial Intelligence
Top stock movements in today's session. ↗
Via Chartmill
Myriad Genetics (NASDAQ:MYGN) Plunges 26% After Fiscal Q2 Revenue and EPS Miss, Slashes Full-Year Guidance ↗
Via Chartmill
Myriad Genetics (NASDAQ:MYGN) Plunges 14% After Q1 Earnings Beat Revenue Estimates But Miss EPS ↗
Via Chartmill
Topics Earnings
Gapping stocks in Friday's session ↗
Via Chartmill
Friday's pre-market session: top gainers and losers ↗
Via Chartmill
Thursday's after hours session: top gainers and losers ↗
Via Chartmill
News headline image
Myriad Genetics (NASDAQ:MYGN) Reports Sales Below Analyst Estimates In Q2 CY2026 Earnings, Stock Drops 28.6%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) fell short of the market’s revenue expectations in Q2 CY2026, with sales falling 10.5% year on year to ... 
Via StockStory
Topics Artificial Intelligence
News headline image
Myriad Genetics (MYGN) Reports Q2: Everything You Need To Know Ahead Of Earnings
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Thursday after market hours. Here’s what you need to know. Myriad Genet... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Unprofitable Stocks That Fall Short
Unprofitable companies face headwinds as they struggle to keep operating expenses under control. Some may be investing heavily, but the majority fail to conv... 
Via StockStory
News headline image
3 Reasons MYGN is Risky and 1 Stock to Buy Instead
Myriad Genetics has been treading water for the past six months, recording a small loss of 3.6% while holding steady at $5.66. The stock also fell short of t... 
Via StockStory
News headline image
1 Unpopular Stock That Should Get More Attention and 2 We Find Risky
Wall Street has issued downbeat forecasts for the stocks in this article. These predictions are rare - financial institutions typically hesitate to say bad t... 
Via StockStory
News headline image
Spotting Winners: Myriad Genetics (NASDAQ:MYGN) And Therapeutics Stocks In Q1
Wrapping up Q1 earnings, we look at the numbers and key takeaways for the therapeutics stocks, including Myriad Genetics (NASDAQ:MYGN) and its peers. Over th... 
Via StockStory
Topics Artificial Intelligence
News headline image
Why Is Myriad Genetics (MYGN) Stock Rocketing Higher Today
What Happened? Shares of genetic testing company Myriad Genetics (NASDAQ:MYGN) jumped 9.2% in the morning session after the company expanded the availability... 
Via StockStory
News headline image
1 Cash-Burning Stock with Promising Prospects and 2 Facing Headwinds
Companies that burn cash at a rapid pace can run into serious trouble if they fail to secure funding. Without a clear path to profitability, these businesses... 
Via StockStory
Topics Bankruptcy
News headline image
3 High-Flying Stocks We’re Skeptical Of
Expensive stocks typically earn their valuations through superior growth rates that other companies simply can’t match. The flip side though is that these lo... 
Via StockStory
News headline image
1 Unprofitable Stock to Consider Right Now and 2 We Turn Down
Unprofitable companies can burn through cash quickly, leaving investors exposed if they fail to turn things around. Without a clear path to profitability, th... 
Via StockStory
Topics Energy
News headline image
Myriad Genetics’s Q1 Earnings Call: Our Top 5 Analyst Questions
Myriad Genetics began 2026 with results that fell short of Wall Street’s expectations, as the company posted modest year-over-year sales growth but missed on... 
Via StockStory
Topics Earnings
News headline image
3 of Wall Street’s Favorite Stocks with Open Questions
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these f... 
Via StockStory
News headline image
MYGN Q1 Deep Dive: Hereditary Cancer Strength, Launch Investments Pressure Margins
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 millio... 
Via StockStory
News headline image
Myriad Genetics (NASDAQ:MYGN) Misses Q1 CY2026 Sales Expectations, Stock Drops 16.2%
Genetic testing company Myriad Genetics (NASDAQ:MYGN) missed Wall Street’s revenue expectations in Q1 CY2026 as sales rose 2.3% year on year to $200.4 millio... 
Via StockStory
News headline image
Myriad Genetics (MYGN) To Report Earnings Tomorrow: Here Is What To Expect
Genetic testing company Myriad Genetics (NASDAQ:MYGN) will be reporting earnings this Tuesday after market close. Here’s what you need to know. Myriad Geneti... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Small-Cap Stocks We Think Twice About
Small-cap stocks can be incredibly lucrative investments because their lack of analyst coverage leads to frequent mispricings. However, these businesses (and... 
Via StockStory
News headline image
1 Cash-Burning Stock to Target This Week and 2 We Question
Rapid spending isn’t always a sign of progress. Some cash-burning businesses fail to convert investments into meaningful competitive advantages, leaving them... 
Via StockStory
News headline image
Q4 Earnings Highlights: Myriad Genetics (NASDAQ:MYGN) Vs The Rest Of The Therapeutics Stocks
Quarterly earnings results are a good time to check in on a company’s progress, especially compared to its peers in the same sector. Today we are looking at ... 
Via StockStory
Topics Artificial Intelligence
News headline image
3 Healthcare Stocks with Open Questions
From novel pharmaceuticals to telemedicine, most healthcare companies are on a mission to drive better patient outcomes. Players catalyzing medical advanceme... 
Via StockStory
News headline image
Elanco, Tandem Diabetes, Fortrea, Natera, and Myriad Genetics Shares Plummet, What You Need To Know
What Happened? A number of stocks fell in the afternoon session after major indices including the S&P 500 and Dow Jones Industrial Average fell sharply as in... 
Via StockStory
Topics Government Stocks
News headline image
2 High-Flying Stocks with Competitive Advantages and 1 We Brush Off
"You get what you pay for" often applies to expensive stocks with best-in-class business models and execution. While their quality can sometimes justify the ... 
Via StockStory
< Previous 1 2 3 4 5 6 7 8 9 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.